174 related articles for article (PubMed ID: 23217168)
1. The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study.
Yang YH; Yang YH; Cheng CL; Ho PS; Ko YC
BMC Cancer; 2012 Dec; 12():582. PubMed ID: 23217168
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study.
Vinogradova Y; Hippisley-Cox J; Coupland C; Logan RF
Gastroenterology; 2007 Aug; 133(2):393-402. PubMed ID: 17681160
[TBL] [Abstract][Full Text] [Related]
4. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Harris RE; Beebe-Donk J; Alshafie GA
Int J Biol Sci; 2007 Jun; 3(5):328-34. PubMed ID: 17589567
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase as a target for colorectal cancer chemoprevention.
Moreira L; Castells A
Curr Drug Targets; 2011 Dec; 12(13):1888-94. PubMed ID: 21158711
[TBL] [Abstract][Full Text] [Related]
6. Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
Huang WW; Hsieh KP; Huang RY; Yang YH
Kaohsiung J Med Sci; 2017 Jun; 33(6):308-314. PubMed ID: 28601236
[TBL] [Abstract][Full Text] [Related]
7. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis.
Ladabaum U; Scheiman JM; Fendrick AM
Am J Med; 2003 May; 114(7):546-54. PubMed ID: 12753878
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of colorectal neoplasia.
Wakeman C; Keenan J; Eteuati J; Hollington P; Eglinton T; Frizelle F
ANZ J Surg; 2017 Dec; 87(12):E228-E232. PubMed ID: 26686322
[TBL] [Abstract][Full Text] [Related]
9. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2006 Jan; 6():27. PubMed ID: 16445867
[TBL] [Abstract][Full Text] [Related]
10. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
11. Association between Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer: A Population-Based Case-Control Study.
Kuo CN; Pan JJ; Huang YW; Tsai HJ; Chang WC
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):737-745. PubMed ID: 29695380
[No Abstract] [Full Text] [Related]
12. Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis.
He P; Yang C; Ye G; Xie H; Zhong W
Colorectal Dis; 2019 Apr; 21(4):417-426. PubMed ID: 30656820
[TBL] [Abstract][Full Text] [Related]
13. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
Arber N
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371
[TBL] [Abstract][Full Text] [Related]
15. Statin use and the risk of colorectal cancer: a population-based case-control study.
Cheng MH; Chiu HF; Ho SC; Tsai SS; Wu TN; Yang CY
World J Gastroenterol; 2011 Dec; 17(47):5197-202. PubMed ID: 22215945
[TBL] [Abstract][Full Text] [Related]
16. Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control.
Rodríguez-Miguel A; García-Rodríguez LA; Gil M; Barreira-Hernández D; Rodríguez-Martín S; de Abajo FJ
Aliment Pharmacol Ther; 2019 Aug; 50(3):295-305. PubMed ID: 31313358
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Rostom A; Dubé C; Lewin G; Tsertsvadze A; Barrowman N; Code C; Sampson M; Moher D;
Ann Intern Med; 2007 Mar; 146(5):376-89. PubMed ID: 17339623
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
